Intellia Therapeutics Inc
NTLA12.250USD
+0.760+6.61%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.27BCap. mercado
PérdidaP/E TTM
Más Datos de Intellia Therapeutics Inc Compañía
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
Información de la empresa
Símbolo de cotizaciónNTLA
Nombre de la empresaIntellia Therapeutics Inc
Fecha de salida a bolsaMay 06, 2016
Director ejecutivoDr. John M. Leonard, M.D.
Número de empleados403
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 06
Dirección40 Erie St Ste 130
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02139-4254
Teléfono18572856200
Sitio Webhttps://www.intelliatx.com/
Símbolo de cotizaciónNTLA
Fecha de salida a bolsaMay 06, 2016
Director ejecutivoDr. John M. Leonard, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Mr. Brian M. Goff
Mr. Brian M. Goff
Independent Director
Independent Director
23.41K
+51.92%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
19.97K
+66.85%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
18.80K
+74.05%
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
16.62K
-8.51%
Mr. Michael P. Dube
Mr. Michael P. Dube
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
4.52K
-35.64%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
893.46K
+10.09%
Ms. Eliana Clark, Ph.D.
Ms. Eliana Clark, Ph.D.
Executive Vice President, Chief Technology Officer
Executive Vice President, Chief Technology Officer
92.38K
-1.09%
Dr. David Lebwohl, M.D.
Dr. David Lebwohl, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
51.64K
+125.03%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
49.72K
+19.18%
Dr. Georgia Keresty, Ph.D.
Dr. Georgia Keresty, Ph.D.
Independent Director
Independent Director
24.15K
+49.55%
Mr. Brian M. Goff
Mr. Brian M. Goff
Independent Director
Independent Director
23.41K
+51.92%
Desglose de ingresos
FY2025Q1
FY2024
FY2023
FY2022
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
16.63M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 18 de jul
Actualizado: vie., 18 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
12.57%
The Vanguard Group, Inc.
10.36%
BlackRock Institutional Trust Company, N.A.
8.12%
State Street Global Advisors (US)
4.35%
Two Sigma Investments, LP
3.84%
Other
60.76%
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
12.57%
The Vanguard Group, Inc.
10.36%
BlackRock Institutional Trust Company, N.A.
8.12%
State Street Global Advisors (US)
4.35%
Two Sigma Investments, LP
3.84%
Other
60.76%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
50.59%
Investment Advisor/Hedge Fund
20.47%
Hedge Fund
14.23%
Research Firm
6.53%
Corporation
3.57%
Individual Investor
1.49%
Bank and Trust
0.78%
Pension Fund
0.32%
Private Equity
0.22%
Other
1.79%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
699
101.80M
98.27%
-16.60M
2025Q1
734
106.27M
102.60%
-9.72M
2024Q4
721
99.85M
96.57%
-1.86M
2024Q3
722
94.22M
92.84%
-2.81M
2024Q2
726
90.26M
93.51%
-7.71M
2024Q1
739
91.00M
94.49%
-893.96K
2023Q4
792
85.05M
91.49%
-3.09M
2023Q3
802
83.74M
94.78%
-6.96M
2023Q2
821
81.86M
93.61%
-7.70M
2023Q1
811
82.36M
94.28%
-4.97M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
ARK Investment Management LLC
13.01M
12.56%
+474.63K
+3.79%
Mar 31, 2025
The Vanguard Group, Inc.
10.73M
10.36%
+561.98K
+5.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.41M
8.12%
-411.95K
-4.67%
Mar 31, 2025
State Street Global Advisors (US)
4.51M
4.35%
-695.44K
-13.36%
Mar 31, 2025
Two Sigma Investments, LP
3.98M
3.84%
+120.05K
+3.11%
Mar 31, 2025
Capital International Investors
3.78M
3.65%
+3.78M
--
Mar 31, 2025
Regeneron Pharmaceuticals Inc
3.70M
3.57%
--
--
Mar 31, 2025
Citadel Advisors LLC
2.76M
2.66%
+263.50K
+10.56%
Mar 31, 2025
Nikko Asset Management Co., Ltd.
2.83M
2.73%
-167.30K
-5.59%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.48M
2.39%
+90.93K
+3.81%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ARK Genomic Revolution ETF
2.65%
WisdomTree BioRevolution Fund
2.48%
ARK Innovation ETF
1.25%
Global X Genomics & Biotechnology ETF
1.17%
Virtus LifeSci Biotech Clinical Trials ETF
1.01%
Tema Neuroscience and Mental Health ETF
0.54%
SPDR S&P Biotech ETF
0.31%
Tema Heart & Health ETF
0.23%
Direxion Daily S&P Biotech Bull 3X Shares
0.17%
Avantis US Small Cap Equity ETF
0.12%
Ver más
ARK Genomic Revolution ETF
Proporción2.65%
WisdomTree BioRevolution Fund
Proporción2.48%
ARK Innovation ETF
Proporción1.25%
Global X Genomics & Biotechnology ETF
Proporción1.17%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción1.01%
Tema Neuroscience and Mental Health ETF
Proporción0.54%
SPDR S&P Biotech ETF
Proporción0.31%
Tema Heart & Health ETF
Proporción0.23%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.17%
Avantis US Small Cap Equity ETF
Proporción0.12%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
